Adrenal Suppression Following a Single Dose of Etomidate For Rapid Sequence Induction: A Prospective Randomized Study
Authors:
- Amy N. HildrethAHAmy N. Hildreth
- Vicente A. MejiaVMVicente A. Mejia
- Robert A. MaxwellRMRobert A. Maxwell
- Philip W. SmithPSPhilip W. Smith
- Benjamin W. DartBDBenjamin W. Dart
- Donald E. BarkerDBDonald E. Barker
- 1 September 2008
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Trauma: Injury, Infection & Critical Care
- Vol. 65 (3) , 573-579
Abstract
The administration of etomidate for rapid sequence induction (RSI) has been linked to subsequent adrenocortical insufficiency in nontrauma patients. However, etomidate-related adrenocortical insufficiency has not been well studied in the trauma population. We performed a prospective, randomized, controlled study to assess the effect of one dose of etomidate for RSI on adrenal function and its clinical significance during and after resuscitation in trauma patients. Adult trauma patients admitted to our Level I trauma center requiring RSI were randomized to receive etomidate 0.3 mg/kg and succinylcholine 1 mg/kg (E group) or fentanyl 100 microg, midazolam 5 mg, and succinylcholine 1 mg/kg (FM group) for induction. A baseline serum cortisol level was drawn before RSI. Four to six hours after RSI, a postintubation serum cortisol level was drawn. An ACTH stimulation test was performed. Thirty patients were enrolled: 18 E group patients and 12 FM group patients. No statistical difference was detected between the two groups with respect to age, injury severity score, and baseline serum cortisol. Mean serum cortisol levels were significantly lower in E group patients than in FM group patients 4 to 6 hours after intubation (18.2 vs. 27.8 mug/dL, p < 0.05). Change in serum cortisol between baseline and postintubation levels was different (-12.8 mg/dL +/- 9.6 microg/dL vs. 1.1 microg/dL +/- 7.6 microg/dL, p < 0.01). Patients in the E group had an average increase in cortisol after ACTH administration of 4.2 microg/dL +/- 4.9 microg/dL vs. 11.2 microg/dL +/- 6.1 microg/dL in the FM group, p < 0.001. Patients in the E group required longer ICU lengths of stay (mean, 6.3 days vs. 1.5 days, p < 0.05), more ventilator days (mean, 28 days vs. 17 days, p < 0.01), and longer hospital lengths of stay (mean, 11.6 days vs. 6.4 days, p < 0.01). The use of etomidate for RSI in trauma patients led to chemical evidence of adrenocortical insufficiency and may have contributed to increased hospital and ICU lengths of stay and increased ventilator days. Further studies should be considered to evaluate the safety profile of this drug in trauma patients.Keywords
This publication has 30 references indexed in Scilit:
- ETOMIDATE USE IN THE CRITICALLY INJURED PATIENT IS ASSOCIATED WITH AN INCREASED RISK OF ADRENAL INSUFFICIENCY.Critical Care Medicine, 2005
- Adrenocortical function in critically ill patients 24 h after a single dose of etomidateAnaesthesia, 1999
- The Effect of Propofol on Adrenocortical SteroidogenesisAnesthesiology, 1987
- EFFECT OF A SINGLE BOLUS OF ETOMIDATE UPON EIGHT MAJOR CORTICOSTEROID HORMONES AND PLASMA ACTHClinical Endocrinology, 1985
- Wirkung einer Einleitungsdosis von Etomidat, Methohexital und Midazolam auf die Funktion der Nebennierenrinde vor und nach ACTH-StimulationDMW - Deutsche Medizinische Wochenschrift, 1985
- Effects of Etomidate on Hormonal Responses to Surgical StressAnesthesiology, 1984
- Etomidate Inhibits Adrenocortical Function in Surgical PatientsAnesthesiology, 1984
- Adrenocortical suppression by a single induction dose of etomidateJournal of Molecular Medicine, 1984
- Inhibition of Adrenal Steroidogenesis by the Anesthetic EtomidateNew England Journal of Medicine, 1984
- Control of Intracranial Pressure during Pediatric Neurosurgery AnesthesiaPediatric Neurosurgery, 1978